Sign In
Buy HCM
$9.99
-0.290 (-2.82%)
At Close: Jun 22, 2026
HUTCHMED Limited kicks off phase III cancer trial
03:43am, Tuesday, 21'st Sep 2021
HUTCHMED China Limited, currently the largest company on AIM, said it had begun dosing its first patient in a phase III clinical trial of a treatment it is developing for a form of intestinal cancer.
HUTCHMED Limited phase III cancer trial kicks off
03:19am, Tuesday, 21'st Sep 2021
HUTCHMED Limited said it had begun dosing its first patient in a phase III clinical trial of a treatment it is developing for a form of intestinal cancer. The study, taking place in China, will pair t
HONG KONG and FLORHAM PARK, N.J., Sept. 20, 2021 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) today announces that it has initiated SURTORI-01, a Phase III
HUTCHMED Initiates a Japan Bridging Study to Support Surufatinib Registration for Advanced Neuroendocrine Tumors
08:00pm, Sunday, 19'th Sep 2021
Following surufatinib launch in China in January 2021; NDA acceptance by the U.S. FDA for review in June 2021; and MAA validation by the EMA in July 2021 all for advanced neuroendocrine tumors Follow
HUTCHMED's Lymphoma Candidate Secures Breakthrough Tag In China
06:22am, Monday, 13'th Sep 2021
The Center for Drug Evaluation of China's National Medical Products Administration has granted Breakthrough Therapy Designation to HUTCHMED (China) Limited's (NASDAQ: HCM) amdizalisib (HMPL-689).
HONG KONG and SHANGHAI, China and FLORHAM PARK, N,J., Sept. 13, 2021 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) today announces that the Center for Drug
— Follows important findings from the SAVANNAH study of this combination in lung cancer patients whose tumors harbor mutations or aberrations of EGFR and MET — — Follows important findings f
HUTCHMED Highlights Clinical Data to be Presented at the Upcoming 2021 ESMO Virtual Conference
04:30am, Tuesday, 07'th Sep 2021
HONG KONG, SHANGHAI, China and FLORHAM PARK, N.J., Sept. 07, 2021 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM, HKEX: 13) today announces that new analyses and update
HUTCHMED Announces Selection of Its Shares in the Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect Programs
02:00am, Monday, 06'th Sep 2021
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Sept. 06, 2021 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) today announces that the Company's ordina
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Aug. 25, 2021 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX:13) has initiated a Phase Ib/II study of fruqui
HUTCHMED Selected as Constituent of Certain Hang Seng Indexes
08:00pm, Sunday, 22'nd Aug 2021
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Aug. 22, 2021 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) today announces that HUTCHMED has been sel
Epizyme Stock Gains On Potential $310M Pact With HUTCHMED For Cancer-Focused Tazverik In Greater China
06:15am, Monday, 09'th Aug 2021
Epizyme Inc (NASDAQ: EPZM) and HUTCHMED (China) Limited (NASDAQ: HCM) have collaborated to research, develop, manufacture, and commercialize Tazverik (tazemetostat) in Greater China, including ma
HUTCHMED and Epizyme Announce Strategic Collaboration to Develop and Commercialize TAZVERIK® (tazemetostat) in Greater China
08:00pm, Sunday, 08'th Aug 2021
Collaboration designed to accelerate global development and investigate TAZVERIK ® combinations with HUTCHMED's novel oncology medicines portfolio
Health Care, BioTech Are Highly Regulated Globally: Hutchmed
01:02am, Thursday, 29'th Jul 2021
Jul.29 -- Christian Hogg, chief executive officer at Hutchmed, a cancer drug developer, discusses China's regulatory crackdown, doing business in China and the outlook for the biotech sector. He speak
Hutchmed Stock Gains On Kick Starting Mid-Stage Gastric Cancer Trial With AstraZeneca's Orpathys
07:02am, Wednesday, 28'th Jul 2021
HUTCHMED (China) Limited (NASDAQ: HCM) and AstraZeneca Plc (NASDAQ: AZN) have initiated a Phase 2 study of Orpathys (savolitinib) in patients with advanced or metastatic MET amplified gastric can
